98 results
Page 2 of 5
424B5
n94 gold1kedv
4 Aug 20
Prospectus supplement for primary offering
9:32am
8-K
EX-99.1
o41ac2
4 Aug 20
Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing
9:29am
8-K
EX-99.1
ddn4y5dcmfq2tu0n9
22 Jul 20
Regulation FD Disclosure
10:00am
8-K
EX-99.1
3jaa2qlm4m01
20 Jul 20
Regulation FD Disclosure
3:09pm
8-K
EX-99.1
vdj10u
19 Jun 20
Regulation FD Disclosure
5:27pm
8-K
EX-99.1
aa6tihoml63vv9xg2h2d
26 May 20
Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line
2:15pm
8-K
EX-99.1
tcfcdy9b
21 May 20
Regulation FD Disclosure
9:32am
8-K
EX-99.1
ndii 3ohh0vrx6
28 Apr 20
Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4
9:30am
8-K
EX-99.1
dx71329x 8r64
6 Apr 20
Regulation FD Disclosure
2:21pm
8-K
EX-99.1
8twyq2n
1 Apr 20
Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19
12:00pm
8-K
EX-99.1
v79du3
6 Mar 20
Innovation Pharmaceuticals Signs Second MTA to Explore Brilacidin as Coronavirus
12:00pm
8-K
EX-99.1
ak28l04sg8
27 Feb 20
Regulation FD Disclosure
12:00pm
8-K
EX-99.1
640resl0m7 eg6j
13 Feb 20
Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin
4:05pm
424B3
xd6m784xint b7c9
16 Dec 19
Prospectus supplement
8:31am
POS AM
b08ak8i62nuz qvxfb3
17 Oct 19
Prospectus update (post-effective amendment)
5:23pm